Caricamento...

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies. The risk of relapse and sustained accumulation of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ther Clin Risk Manag
Autori principali: Guarnera, Cristina, Bramanti, Placido, Mazzon, Emanuela
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2017
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5522829/
https://ncbi.nlm.nih.gov/pubmed/28761351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S134398
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !